We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
- Authors
Kosi‐Trebotic, Lana; Thomas, Anita; Harreiter, Jürgen; Chmelik, Marek; Trattnig, Siegfried; Kautzky‐Willer, Alexandra
- Abstract
Background Increased hepatic fat and cardiac fat are common in patients with type 2 diabetes mellitus (T2 DM) and are associated with a greater risk of liver fibrosis and cardiovascular ( CV) events. Sex-specific differences of dipeptidyl peptidase-four ( DPP-4) inhibitor effects on hepatic ( HCL) and myocardial fat content ( MYCL) have not yet been evaluated. Method Forty-one T2 DM patients (20 male, 21 female) received a gliptin add-on therapy if HbA1c goals were not reached under metformin monotherapy. They underwent cardiac and liver magnetic resonance tomography and spectroscopy before and 6 months after therapy initiation. Plasma samples were analysed for the growth differentiation factor 15 ( GDF-15), a novel marker for cardiovascular risk. Results Thirty-eight patients on gliptin therapy completed the study. We observed a positive correlation between MYCL and HCL before therapy ( R = 0·41, P = 0·05). After 6 months of therapy, we noticed a significant weight reduction in women only ( P = 0·02) whereas waist circumference decreased similarly in both sexes. HbA1c sunk significantly in both sexes ( P = 0·002). HCL decreased significantly ( P = 0·0004), with women featuring higher basal HCL ( P < 0·05). MYCL decreased in women only ( P = 0·01) and GDF-15 comparably in both sexes ( P < 0·05). Conclusions 6 months of DPP-4-therapy led to a significant overall decrease in HCL and body weight such as a reduction of MYCL only in women. This preliminary data set could implicate that gliptin may be a feasible therapy option in fatty liver patients with diabetes potentially including positive effects on cardiovascular function particularly in women.
- Subjects
FIBROSIS; COLLAGEN diseases; CARDIOVASCULAR diseases; MAGNETIC resonance; METFORMIN; HYPOGLYCEMIC agents; BODY weight
- Publication
European Journal of Clinical Investigation, 2017, Vol 47, Issue 11, p829
- ISSN
0014-2972
- Publication type
Article
- DOI
10.1111/eci.12817